Payment overview · 2025
General Payments
$9,435.89
14 reported records · 9 companies
Healthcare provider profile · identity verified
Anthony Langone, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · NASHVILLE, TN · NPI 1841387974
Verified facts
What the public records show
CMS Open Payments records show Anthony Langone, MD received $9,435.89 in general payments during 2025 across 14 reported records.
Veloxis Pharmaceuticals, Inc. accounted for 73.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Veloxis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6,900.00 | 73.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $1,427.04 | 15.1% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $509.85 | 5.4% | 4 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.19 | 1.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $138.15 | 1.5% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $132.45 | 1.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $99.42 | 1.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $37.84 | 0.4% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.95 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $8,262.50 | 2 |
| Food and Beverage | $1,108.85 | 10 |
| Education | $64.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENVARSUS Normalized: envarsus |
Drug | Veloxis Pharmaceuticals, Inc. | $6,900.00 | 1 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $158.19 | 1 | 2025 |
Source payment records
|
|||||
| THYMOGLOBULIN Normalized: thymoglobulin |
Biological | GENZYME CORPORATION | $138.15 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $132.45 | 1 | 2025 |
Source payment records
|
|||||
| NULOJIX Normalized: nulojix |
Biological | E.R. Squibb & Sons, L.L.C. | $99.42 | 1 | 2025 |
Source payment records
|
|||||
| Rivfloza Normalized: rivfloza |
Drug | Novo Nordisk Inc | $64.54 | 2 | 2025 |
Source payment records
|
|||||
| LIVTENCITY Normalized: livtencity |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $37.84 | 1 | 2025 |
Source payment records
|
|||||
| OXLUMO Normalized: oxlumo |
Drug | Alnylam Pharmaceuticals Inc. | $32.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 365 | 96 |
| Nifedipine Er | Nifedipine | 361 | 108 |
| Telmisartan | Telmisartan | 260 | 84 |
| Pravastatin Sodium | Pravastatin Sodium | 239 | 72 |
| Omeprazole | Omeprazole | 228 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 70 |
| Carvedilol | Carvedilol | 184 | 64 |
| Irbesartan | Irbesartan | 179 | 48 |
| Allopurinol | Allopurinol | 165 | 50 |
| Famotidine | Famotidine | 114 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 88 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 77 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 12 |
| Furosemide | Furosemide | 71 | 22 |
| Fluconazole | Fluconazole | 67 | 16 |
| Potassium Chloride | Potassium Chloride | 60 | 22 |
| Tacrolimus | Tacrolimus | 55 | 13 |
| Ezetimibe | Ezetimibe | 54 | 17 |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 40 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 11 |
| Valacyclovir | Valacyclovir Hcl | 39 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 38 | 14 |
| Sertraline Hcl | Sertraline Hcl | 38 | 11 |
| Temazepam | Temazepam | 38 | suppressed |
| Gabapentin | Gabapentin | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Losartan Potassium | Losartan Potassium | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | 13 |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Lisinopril | Lisinopril | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,435.89 · 14 records | Veloxis Pharmaceuticals, Inc. | ENVARSUS, Empaveli, LIVTENCITY, NULOJIX, OXLUMO, Rivfloza, TARPEYO, THYMOGLOBULIN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error